<DOC>
	<DOCNO>NCT02740218</DOCNO>
	<brief_summary>This retrospective , multi-center observational cohort study . This study implement first Germany ( approximately 50 site ) , United Kingdom ( approximately 20 site ) Sweden ( approximately 25 site ) , follow select number country Europe , depend apremilast local availability . The design apremilast retrospective study aim provide clinical information regard treatment initiation outcome psoriasis patient prescribe apremilast real world setting . In addition , study aim capture physician ' patient ' treatment goal initiate apremilast whether goal achieve follow apremilast use . This study primarily descriptive nature , priori hypothesis specify . Patients must voluntarily sign informed consent form , 18 , diagnose plaque psoriasis treat apremilast previous 5-7 month participate study . They must involve clinical study involve apremilast .</brief_summary>
	<brief_title>A Study Real-World Experience Psoriasis Patients Treated With Apremilast Clinical Dermatology Practice</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Must understand voluntarily sign Informed Consent Form ( ICF ) . 2 . Age â‰¥ 18 year time sign ICF . 3 . Diagnosed plaque psoriasis . 4 . Initiated treatment apremilast 6 month ( +/ 1 month ) previously ( patient may may complete 6 month apremilast treatment ) 1 . Refusal participate study current participation treatment phase interventional clinical trial . 2 . Started apremilast part clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Apremilast</keyword>
	<keyword>APPRECIATE</keyword>
	<keyword>Dermatology</keyword>
	<keyword>Retrospective</keyword>
	<keyword>Observational</keyword>
</DOC>